Floatz logo

Cipralex

Treatment Outcome

TakedaPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Treatment Outcome cohort.

Asset / SponsorPhaseRating
Vortioxetine
Takeda
Phase 3BB
Dexborneol
Xiangya Hospital of Central South University
Phase 3B
Compound Edaravone
Xiangya Hospital of Central South University
Phase 3B
Erythropoietin Human Recombinant
Bundang CHA Hospital
Phase 1/2CCC
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD
Bundang CHA Hospital
Phase 1/2CCC
FLUMAZENIL
Anders Jørgensen
N/AD

Same molecule, other indications

Cipralex is also rated in:

Anxiety DisordersDormant
A
Indicative ·
81 / 100
View asset →
bipolar I disorderDormant
BBB
Indicative ·
77 / 100
View asset →
dysthymic disorderDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →